New hope for AML patients: experimental drug combo tested

NCT ID NCT05319587

Completed Disease control Sponsor: Moleculin Biotech, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called liposomal annamycin combined with standard chemotherapy (cytarabine) in 22 adults with acute myeloid leukemia (AML). The goal was to find the safest dose and see if the combination can control the disease. Participants had either newly diagnosed or relapsed/refractory AML. The study is complete, and results will help guide future treatment options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOID, ACUTE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEUKEMIA, MYELOID, ACUTE

Contacts and locations

Locations

Apteka Szpitalna

Gdansk, Poland
Fondazione Policlinico Universitario A. Gemelli IRCCS

Roma, Italy
IRCCS Azienda Ospedaliero-Universitaria di Bologna

Bologna, 40138, Italy
Instytut Hematologii i Transfuzjologii, Klinika Hematologii, Warsaw

Warsaw, Poland
Istituto Scientifico Romagolo per lo studio dei umori "Dino Amadori" (IRST) - IRCCS

Meldola, FC, 47014, Italy
SP ZOZ MsWiA z Warminsko-Mazurksim Centrum Onkologii w Olsztynie Oddzial Kliniczny Hematologii

Olsztyn, Warmian-Masurian Voivodeship, 10-228, Poland
Samodzielny Publiczny Szpital Kliniczny nr 1 im. Prof. Tadeusza Sokołowskiego w Szczecinie, Klinika Hematologii z Oddziałem Transplantacji Szpiku, Szczecin

Szczecin, Poland
Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego

Poznan, Poland
Uniwersytecki Szpital Kliniczny Klinika Hematologii Nowotworow

Wroclaw, Dolnośląskie Województwo, 50-367, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.